Literature DB >> 15823605

Vpu-mediated CD4 down-regulation and degradation is conserved among highly divergent SIV(cpz) strains.

Lisa M Gomez1, Erik Pacyniak, Melissa Flick, David R Hout, Melissa L Gomez, Eric Nerrienet, Ahidjo Ayouba, Mario L Santiago, Beatrice H Hahn, Edward B Stephens.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) along with simian immunodeficiency viruses from chimpanzees (SIV(cpz)) and three species of Old World monkeys from the genus Cercopithecus have been shown to encode a Vpu protein. To date, the functional characterization of Vpu has been limited to a small number of subtype B and more recently subtype C Vpu proteins. Using a recently developed VpuEGFP reporter system, we have shown that the subtype B and C Vpus are capable of preventing CD4 from being expressed on the cell surface. Using the same reporter system, we report here on the expression and functional analysis of Vpu protein from four SIV(cpz) isolates (CAM13, ANT, TAN1, and GAB1). All four SIV Vpu fusion proteins were efficiently expressed and prevented CD4 expression on the cell surface and induced CD4 degradation. This was surprising as three of the SIV(cpz) Vpu fusion proteins had only one canonical casein kinase II (CK-II) site (CAM13, ANT, TAN1) while previous studies with laboratory adapted HXB2 had indicated that both CK-II sites were required for CD4 degradation. Both ANT and TAN1 Vpu sequences encoded five consecutive negatively charged amino acids residues following the only CKII site (SAIEEDEE for ANT; SGVEEDEE for TAN1). We thus explored the possibility that this stretch of negatively charged amino acids might substitute for the lack of second CK-II site. Substitution of the aspartic acid at position 61 and glutamic acid at position 63 in the SIV(cpz) ANT Vpu within with lysine residues abolished the ability of this protein to down-modulate cell surface expression of CD4. Similarly, change of a serine to an alanine residue following the single consensus CK-II site of the CAM13 Vpu (SGNESDGGEEE) abolished CD4-down-regulation, suggesting that this serine was phosphorylated in the absence of a canonical CK-II site. Our results indicate that the serine was required, suggesting that this serine was phosphorylated by CK-II or possibly another cellular kinase. Taken together, these results show for the first time that Vpu proteins from SIV(cpz) isolates, although quite diverse in sequence and predicted secondary structure from the HIV-1 subtype B protein, are capable of down-regulating CD4, which is one of the major functions of the HIV-1 protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823605     DOI: 10.1016/j.virol.2005.01.049

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

2.  Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

3.  Evidences for viral strain selection in late stages of HIV infection: an analysis of Vpu alleles.

Authors:  Marcos Vinícius Pereira Gondim; Joaquim Xavier da Silva; Francisco Prosdocimi; Eduardo Leonardecz-Neto; Octávio Luiz Franco; Enrique Roberto Argañaraz
Journal:  Protein J       Date:  2012-02       Impact factor: 2.371

4.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

5.  Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.

Authors:  M Sarah Hill; Autumn Ruiz; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

6.  Simian-Human immunodeficiency viruses expressing chimeric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmembrane domains in the rate of CD4(+) T cell loss in macaques.

Authors:  Autumn Ruiz; Kimberly Schmitt; Nathan Culley; Edward B Stephens
Journal:  Virology       Date:  2012-12-05       Impact factor: 3.616

7.  Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; John Guatelli; Edward B Stephens
Journal:  Virology       Date:  2008-06-24       Impact factor: 3.616

8.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

9.  Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release.

Authors:  Aneeza Salim; Lee Ratner
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

10.  Anti-tetherin activities in Vpu-expressing primate lentiviruses.

Authors:  Su Jung Yang; Lisa A Lopez; Heiko Hauser; Colin M Exline; Kevin G Haworth; Paula M Cannon
Journal:  Retrovirology       Date:  2010-02-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.